Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.

Journal of neuro-oncology - 1 Sept 2015

Iwadate Yasuo, Matsutani Tomoo, Hirono Seiichiro, Ikegami Shiro, Shinozaki Natsuki, Saeki Naokatsu

Abstract excerpt

Despite accumulating knowledge regarding molecular backgrounds, the optimal management strategy for low-grade gliomas remains controversial. One reason is the marked heterogeneity in the clinical course. To establish an accurate subclassification of low-grade gliomas, we retrospectively evaluated isocitrate dehydrogenase-1 (IDH1) mutation in clinical specimens of diffuse astrocytomas (DA) and oligodendroglial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Chromosomes, Human, Pair 19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Isocitrate Dehydrogenase

Share to Ki-67 Antigen

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to Oligodendroglioma

Share to Radiotherapy

Source

Identifiers

PMID: 26243269
DOI: 10.1007/s11060-015-1863-5

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.PMID 26243269Read ↗

Molecular markers in low-grade gliomas: predictive or prognostic?Semantic proximity Read ↗

Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.Semantic proximity Read ↗

Molecular classification of low-grade diffuse gliomas.Semantic proximity Read ↗

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.Semantic proximity Read ↗

Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.Semantic proximity Read ↗

A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.Semantic proximity Read ↗

Immunohistochemical profiles of I DH 1, MGMT and P 53: Practical significance for prognostication of patients with diffuse gliomasSemantic proximity Read ↗

Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.Semantic proximity Read ↗

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.Semantic proximity Read ↗

Moving toward molecular classification of diffuse gliomas in adultsSemantic proximity Read ↗

Predictive and prognostic factors for gliomas.Semantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.